Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.43 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.43 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.43 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.43 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.43 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.43 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.43 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138266 | 0.85 | ESRRG (0.43) | CCR2KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31189194 | 0.84 | KDM4E (0.56) | KDM4EGLAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL13958729 | 0.84 | KDM4E (0.56) | KDM4EGLAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL3133296 | 0.84 | CCR2 (0.47) | CCR2KDM4ECCR3SMN1; SMN2ALDH1A1 | |
| SCHEMBL31161002 | 0.82 | KDM4E (0.50) | CCR2KDM4EGLAPSMB11PSMA7 | |
| SCHEMBL3131393 | 0.81 | PSMB11 (0.54) | CCR2KDM4EGLAPSMB11PSMA7 | |
| SCHEMBL9277792 | 0.78 | KDM4E (0.56) | CCR2KDM4EGLAMAPTPOLB | |
| SCHEMBL13820351 | 0.77 | KDM4E (0.47) | CCR2KDM4EGLAMAPTPOLB | |
| SCHEMBL15284054 | 0.73 | KDM4E (0.58) | KDM4EGLAMAPTPOLBSMN1; SMN2 | |
| SCHEMBL2030888 | 0.73 | KDM4E (0.61) | KDM4EGLAMAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| EP-2069315-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. Organon (NL) | 2009-06-17 | — | — | EP | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| WO-2008033764-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033764-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | CCR2 3951/4885KDM4E 2909/4885GLA 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.